Cargando…

Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism

PURPOSE: The purpose of this study was to conduct cognitive debriefing (CD) interviews with adults diagnosed with chronic hypoparathyroidism (HP) to assess the content validity of the SF-36v2® Health Survey Acute (SF-36v2) measure in this population. METHODS: CD interviews were conducted with adults...

Descripción completa

Detalles Bibliográficos
Autores principales: Brod, Meryl, Waldman, Laura Tesler, Shu, Aimee D., Smith, Alden
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172226/
https://www.ncbi.nlm.nih.gov/pubmed/36759379
http://dx.doi.org/10.1007/s11136-023-03352-x
_version_ 1785039577276219392
author Brod, Meryl
Waldman, Laura Tesler
Shu, Aimee D.
Smith, Alden
author_facet Brod, Meryl
Waldman, Laura Tesler
Shu, Aimee D.
Smith, Alden
author_sort Brod, Meryl
collection PubMed
description PURPOSE: The purpose of this study was to conduct cognitive debriefing (CD) interviews with adults diagnosed with chronic hypoparathyroidism (HP) to assess the content validity of the SF-36v2® Health Survey Acute (SF-36v2) measure in this population. METHODS: CD interviews were conducted with adults with HP in the United States (US). Interviews were conducted by a trained moderator using a semi-structured interview guide, employing a think-aloud method in conjunction with verbal probing. Participants were asked whether each item was understandable, relevant, important, and sensitive to change in relation to HP. Additionally, comprehension of instructions, response options, and the appropriateness of a 1-week recall period was assessed. RESULTS: Sixteen adults with HP participated in individual CD telephone interviews. All items in the SF-36v2 were reported to be understood, relevant, important, and sensitive to change by at least half, and in most cases, by a strong majority of study participants. Most of the study sample confirmed comprehension of the instructions and the entire sample understood all response options. CONCLUSION: The study findings show that the items in the SF-36v2® are applicable to adults with HP. The overall high levels of endorsement of items provide strong evidence of the measure’s content validity for this population. The SF-36v2 is therefore recommended for usage in clinical trials examining adults with HP, although it is recommended that this generic measure be supplemented with disease-specific instruments such as the recently developed Hypoparathyroidism Patient Experience Scale—Symptom (HPES-Symptom) and Hypoparathyroidism Patient Experience Scale—Impact (HPES-Impact) measures.
format Online
Article
Text
id pubmed-10172226
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101722262023-05-12 Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism Brod, Meryl Waldman, Laura Tesler Shu, Aimee D. Smith, Alden Qual Life Res Article PURPOSE: The purpose of this study was to conduct cognitive debriefing (CD) interviews with adults diagnosed with chronic hypoparathyroidism (HP) to assess the content validity of the SF-36v2® Health Survey Acute (SF-36v2) measure in this population. METHODS: CD interviews were conducted with adults with HP in the United States (US). Interviews were conducted by a trained moderator using a semi-structured interview guide, employing a think-aloud method in conjunction with verbal probing. Participants were asked whether each item was understandable, relevant, important, and sensitive to change in relation to HP. Additionally, comprehension of instructions, response options, and the appropriateness of a 1-week recall period was assessed. RESULTS: Sixteen adults with HP participated in individual CD telephone interviews. All items in the SF-36v2 were reported to be understood, relevant, important, and sensitive to change by at least half, and in most cases, by a strong majority of study participants. Most of the study sample confirmed comprehension of the instructions and the entire sample understood all response options. CONCLUSION: The study findings show that the items in the SF-36v2® are applicable to adults with HP. The overall high levels of endorsement of items provide strong evidence of the measure’s content validity for this population. The SF-36v2 is therefore recommended for usage in clinical trials examining adults with HP, although it is recommended that this generic measure be supplemented with disease-specific instruments such as the recently developed Hypoparathyroidism Patient Experience Scale—Symptom (HPES-Symptom) and Hypoparathyroidism Patient Experience Scale—Impact (HPES-Impact) measures. Springer International Publishing 2023-02-09 2023 /pmc/articles/PMC10172226/ /pubmed/36759379 http://dx.doi.org/10.1007/s11136-023-03352-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Brod, Meryl
Waldman, Laura Tesler
Shu, Aimee D.
Smith, Alden
Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
title Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
title_full Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
title_fullStr Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
title_full_unstemmed Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
title_short Content validation of the SF-36v2® Health Survey Acute for use in hypoparathyroidism
title_sort content validation of the sf-36v2® health survey acute for use in hypoparathyroidism
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172226/
https://www.ncbi.nlm.nih.gov/pubmed/36759379
http://dx.doi.org/10.1007/s11136-023-03352-x
work_keys_str_mv AT brodmeryl contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism
AT waldmanlauratesler contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism
AT shuaimeed contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism
AT smithalden contentvalidationofthesf36v2healthsurveyacuteforuseinhypoparathyroidism